供体游离 DNA 在肾移植中的应用：2020-2021 年进展。
Donor Derived Cell Free DNA in Kidney Transplantation: The Circa 2020-2021 Update.
机构信息
Division of Nephrology, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, United States.
Comprehensive Transplant Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
出版信息
Transpl Int. 2022 Jun 1;35:10448. doi: 10.3389/ti.2022.10448. eCollection 2022.
The routine surveillance of kidney transplant allografts has relied on imperfect non-invasive biomarkers such as creatinine and urinary indices, while the gold standard allograft biopsy is associated with risk of bleeding, organ injury and sampling errors. Donor derived cell free DNA (dd-cfDNA) is being employed as a biomarker that addresses limitations of these surveillance methods, albeit has inherent drawbacks. This review provides an update on the enhanced understanding of dd-cfDNA and its expanded use beyond the conventional indication of detecting allograft rejection.
肾移植同种异体移植物的常规监测依赖于不完美的非侵入性生物标志物，如肌酐和尿指数，而金标准同种异体肾活检与出血、器官损伤和取样误差有关。供体来源的无细胞游离 DNA（dd-cfDNA）被用作一种生物标志物，解决了这些监测方法的局限性，但也存在固有缺陷。本综述提供了对 dd-cfDNA 的增强理解及其在传统检测移植物排斥适应证之外的扩展应用的最新信息。
Zotero 插件